SLC5A2 and type 2 diabetes mellitus: Objective: This study aims to evaluate the effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin, on the prevention of heart failure hospitalizations and the improvement of metabolic control in patients with type 2 diabetes mellitus (T2DM) without documented high cardiovascular risk.